• NSB files new patent in Australia
  • Imugene doses first patient in Phase 1 trial
  • Cronos and MGC Pharma give sales update


NSB announces patent filing in Australia

NeuroScientific Biopharma (ASX:NSB) announced a new patent filing in Australia.

The new patent claims the combination of NSB’s EmtinB drug and Teva’s Copaxone drug resulted in statistically significant increase in neurite length, neuron (cell) survival as well as new myelin formation – in an in-vivo study.

Copaxone, developed by Israeli-based Teva Pharma, is currently registered for the treatment of relapsing Multiple Sclerosis (MS).

Teva’s revenue from worldwide drug sales of Copaxone has reached US$4.2 billion, roughly 21% of the company’s total revenue.

The combination of Copaxone and EmtinB have now been shown to be more effective in treating MS than Copaxone alone.

NSB says this patent provides the opportunity for the company to regain a proprietary position in the MS space.


Imugene doses first patient in Phase 1 trial

Imugene (ASX:IMU) says the first patient has been dosed as part of intravenous (IV) cohort 2 of the Phase 1 MAST (metastatic advanced solid tumours) trial.

The multicenter Phase 1 MAST trial commenced by delivering a low dose of VAXINIA to patients with metastatic or advanced solid tumours, who have had at least two prior lines of standard of care treatment.

VAXINIA is a City of Hope-developed oncolytic virus which has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models.

Once patients in the monotherapy group have been treated with the lowest doses of VAXINIA and acceptable safety has been demonstrated, new study participants will receive combination treatment, CF33-hNIS with the immunotherapy pembrolizumab.

“As recently noted by Professor Yuman Fong in his visit to Australia, the Imugene team continues to progress development of these assets at an excellent pace, and this announcement is yet another example of that,” says Imugene CEO, Leslie Chong.


Sales updates for Cronos and MGC Pharma

Cronos Australia (ASX:CAU) says the one millionth unit of its medicinal cannabis to be sold through the company’s CanView marketplace platform has been shipped today.

The CanView platform was launched in June 2020 and, in less than two and a half years, has sold increasing numbers of units representing quarterly compound growth of more than 40%.

The company now stocks almost 200 product lines on the CanView platform from nearly 30 leading suppliers.

These products represent the majority of the medicinal cannabis products currently available in Australia.

Meanwhile, MGC Pharma (ASX:MXC) has completed the delivery of its largest order of ArtemiC to the US, with a value of US$1 million.

The delivery marks the first substantial commercial delivery of the product under the AMC Holdings’ US supply and distribution agreement to date.

Share prices today: